You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Precision Pathology will develop the CyPath Lung test for early-stage detection of lung cancer as an LDT for commercial sale by the first-quarter of 2019.
Siemens' Atellica BRAHMS PCT assay received clearance from the US Food and Drug Administration on July 16, which the company announced in August.
Fleury will integrate IDbyDNA's Explify platform into its own laboratory workflow and develop a full suite of Explify-based clinical testing.
Expedeon's colloidal gold is an aqueous suspension of uniform, spherical metallic nanoparticles that can conjugate to antibodies and antigens.
The agreement will enable Biocartis to commercialize the EGFR S492R resistance mutation as part of its liquid and solid biopsy RUO assays.
The deal is an extension of an existing agreement involving the license of 14 patents to develop a platform for detecting traumatic brain injury.
LabCorp will be able to develop and commercialize the test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.
Saladax will have the patent rights to Janssen Pharmaceutica's tests that determine drug levels in patients undergoing treatment with antipsychotic drugs.
Beckman said that its assay completes the reproductive menu for its Access immunoassay systems and provides better operational efficiency for labs.
Since purchasing the bioscience unit of Sequenom four years ago, Agena has followed global growth by pushing into more clinical labs in China, as well as Europe.